Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

More and more studies show that men face risks of cancer from BRCA1 and BRCA2 genetic mutations that are most often associated with breast and ovarian cancers in women. According to a JAMA ...

Genetics significantly impact cancer risk, particularly in inherited mutations like BRCA1/BRCA2, which increase ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

Research has identified specific genetic mutations, most notably in the BRCA1 and BRCA2 genes, that increase a man’s risk of developing the disease. Men with these mutations are at higher risk ...

The rise of cancer in younger adults is a wake-up call. Adopting a healthier lifestyle and making small changes today can ...

Britain’s National Health Service (NHS) announced on Thursday that it has begun offering individuals with Jewish ancestry swabs to check for mutations in their BRCA genes, which are associated ...

Susan M. Domchek, MD, FASCOPHILADELPHIA - Susan M. Domchek, MD, FASCO, has been recognized by the American Society of Clinical Oncology (ASCO) with ...